Does Insurance Cover Allergy Shots? Yes — With These Caveats

Yes — virtually all major US insurance plans cover allergy shots (subcutaneous immunotherapy, SCIT) when prescribed by a board-certified allergist for medically necessary IgE-mediated allergic rhinitis, asthma, or insect-sting allergy. Coverage includes BCBS, Aetna, UnitedHealthcare, Cigna, Humana, Anthem, Medicare Part B, every state Medicaid program, and Tricare. The CMS 2025 Physician Fee Schedule confirms Medicare allowed amounts: CPT 95117 at $11.97 per 2+ injection visit; commercial plans average $15.10–$18.05 for the same code per PayerPrice April 2026 transparency files. The binary answer is yes; the nuanced answer involves deductible status, copay stacking, and whether your clinic is hospital-owned.

The five caveats competitor pages skip: (1) FDA-approved SLIT tablets (Grastek, Oralair, Ragwitek, Odactra) go through the pharmacy benefit and always require prior authorization, though office-administered SCIT rarely does for BCBS/Aetna PPO plans; (2) compounded aqueous SLIT drops are considered investigational and not covered by any major payer; (3) HDHP deductible reset — patients starting shots in January owe the full allowed amount for the first 2–3 visits until the deductible is met; (4) copay stacking — Stachler 2020 AAOA calculates $20 copay per shot x 52 weeks x 3 years = $3,120 minimum even on a nominally covered plan; (5) the HOPD facility-fee trap — a hospital-owned allergy clinic can convert a $90 allowed visit into a five-figure bill. All five affect patients who are nominally 'covered.'

Yes — Medicare Part B covers allergy shots (SCIT) under LCD L36240, which designates the Cox et al. 2011 Practice Parameter Third Update as the operative US guideline. After the 2026 Part B deductible of $283 (up from $257 in 2025, per CMS announcement November 14, 2025), patients owe 20% coinsurance on the Medicare allowed amount. For a typical maintenance visit with a 10-dose vial (CPT 95117 + 95165 x 10), the 2025 Medicare allowed amount is $158.82; patient owes $31.76 in 20% coinsurance after deductible is met. A Medigap supplement policy (Plan G or N) eliminates that 20% entirely, making Medicare with Medigap one of the best-covered allergy-shot scenarios available. Medicare does not cover sublingual immunotherapy (NCD 110.9).

No — UnitedHealthcare commercial plans no longer cover home-administered or self-administered SCIT effective January 1, 2023, per the UHC environmental allergen immunotherapy bulletin issued October 2022. This is the most operationally consequential policy change among major commercial carriers in 2022–2025. Office-administered SCIT remains covered under standard UHC commercial PPO/HMO plans without prior authorization; the exclusion applies only to SCIT administered at home by the patient. Patients who were previously receiving home injections under a UHC plan should confirm with their allergist whether their office will administer the shots, since any home-injection arrangement no longer meets UHC benefit criteria.

High-deductible health plans (HDHPs) cover allergy shots but expose patients to full allowed amounts until the annual deductible is met. The IRS-qualified HDHP minimum deductible is $1,650 for self-only coverage in 2026. Patients starting build-up phase in Q1 — when deductibles reset — typically owe $40–$200 per visit for the first 2–4 visits until the deductible burns down. A 40-allergen skin test panel at a freestanding clinic carries a commercial allowed amount of roughly $400; an HDHP patient owes that amount before the first injection. Strategy: schedule the initial skin testing and first build-up injections early in the plan year so the deductible is met before the bulk of the 26-week build-up phase. Post-deductible HDHP coinsurance is typically 20%, so visits drop to $9–$18 per injection afterward.

Three common causes explain most EOB mismatches. First, the visit may have occurred before your deductible was met, triggering the full allowed amount rather than just a copay. Second, the vial-preparation code (CPT 95165) may have been billed on the same day as the injection code (CPT 95117), creating a second line item. Medicare defines a 95165 dose as 1 cc from a single 10-cc vial; commercial payers may define it differently, affecting how many billable units appear. Third — and most important — if your allergist's clinic was acquired by a hospital system and reclassified as a hospital outpatient department (HOPD), a facility fee is added to every visit on top of the professional fee. Ask the billing office whether the clinic is 'provider-based' or 'HOPD-classified' before scheduling if you want to predict your actual out-of-pocket cost.

All 50 state Medicaid programs cover allergy injection codes (CPT 95115/95117), typically at near-zero patient cost share. However, California Medi-Cal explicitly excludes antigen-preparation codes CPT 95120–95134 and 95145–95165 as non-benefits per the DHCS Medi-Cal Allergy Manual Part 2 — meaning practices must either absorb antigen costs or require patients to source antigen elsewhere. EmblemHealth manages New York Medicaid and caps CPT 95165 at 137 units per year. Texas Medicaid STAR pays approximately 92% of Medicare rates per TMPPM Vol. 1 §2, a margin so thin that many Texas practices decline Medicaid SCIT patients. In states where Medicaid coverage is intact, patients typically owe $0–$3 per visit.